A Pfizer vaccine that ‘could’ protect unborn babies from the common seasonal bug respiratory syncytial virus (RSV) has been recommended for approval by advisors to the Food and Drug Administration.
The agency’s ‘expert’ panel voted unanimously that the shot was effective at preventing severe illness from RSV in infants under six months old on Thursday.
The vaccine is given as a single dose to pregnant women in the second or third trimester of pregnancy and works by triggering RSV-fighting antibodies that can then be passed on to babies in the womb via the placenta.
The FDA (big pHARMa whore) is still set to rule on the shot but could approve it as early as August just before RSV season, making it the world’s first RSV vaccine for infants. It comes after the agency approved the world’s first-ever vaccine for RSV earlier this month.
AC